Smart, enzyme-activated MRI contrast agents for cancer detection
Smart, enzyme-activated MRI contrast agents for cancer detection
批准号:
8448578
负责人:
DAVID B SMITHRUD
金额:
$22.21万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-04-01 至 2016-03-31
关键词:
AnimalsArchitectureBindingBiocompatible MaterialsBiologicalBiological AssayBiological MarkersBiological TestingBiomedical ResearchCancer DetectionCancerousCathepsins BCationsCell LineCell physiologyCellsChemistryChoristomaClinicClinicalCommunitiesComplexContrast MediaDataDetectionDevelopmentDiagnosticDiseaseEarly DiagnosisEnzymesExploratory/Developmental GrantFunding MechanismsFutureFuture GenerationsGadoliniumGoalsHydrolysisHypoxiaImageImaging DeviceInterdisciplinary StudyLeadLightMagnetic Resonance ImagingMalignant NeoplasmsMeasuresMedicalMedicineMetalsMethodsModelingMolecular BiologyMonitorMusNMR SpectroscopyOvarianOxidation-ReductionPeptidesPhysiologic pulsePredispositionProcessPropertyProstateProtonsRecoveryResearchResearch PersonnelResolutionResourcesRotaxanesSeriesSignal TransductionSiteSolutionsSpecificityStagingStructureTestingTissuesToxic effectToxicity TestsTrainingTranslationsTreatment EfficacyWaterWorkaqueousbasecancer cellcancer imagingcancer sitecostcytotoxicdesigndisease diagnosisfunctional groupgadolinium oxideimprovedinnovationinterestmetal complexmolecular imagingneoplastic cellnoveloverexpressionresearch and developmentresponsetumortumor growth
中文摘要
描述(由申请人提供):早期发现是根除大多数疾病的关键,特别是癌症。磁共振成像(MRI)是一种强大的,非侵入性的方法来检测体内的异常组织。然而,目前临床上批准的造影剂缺乏对癌细胞的特异性,经历无效的弛豫,并且可能是细胞毒性的。我们提出
一种新型的“智能”MRI试剂,在癌症部位被选择性激活。对于该提议,MRI试剂将通过经由组织蛋白酶B的选择性酶水解而被“打开”,组织蛋白酶B是一种被许多癌细胞过度表达的酶。这种方法不仅大大增强了癌细胞和组织的信号强度,而且与传统的基于Gd 3+的MRI试剂相比,所提出的试剂应该具有更低的毒性并表现出更大的弛豫性。此外,所提出的代理可以在能量独立的过程中进入细胞,以提供在细胞内操作的智能MRI代理。未来的应用包括为MRI试剂配备靶向试剂,以获得更大的细胞/组织选择性。为了检测不过度表达合适酶的癌症,将连接不同类型的开关,其将响应氧化还原化学或pH的变化。该提案的具体目标是创建MRI试剂,其可以在“关闭”和“打开”模式下优化,测试它们对组织蛋白酶B的响应,测量它们的弛豫率值,并确定它们在细胞和小鼠中的毒性。长期目标是为研究人员和医学界提供量身定制的智能MRI试剂,以推进细胞功能的研究,并提供疾病的早期检测,如癌症。
英文摘要
DESCRIPTION (provided by applicant): Early detection is key to eradicating most diseases, especially cancers. Magnetic Resonance Imaging (MRI) is a powerful, noninvasive method to detect aberrant tissues within the body. Current clinically approved contrast agents, however, lack specificity for cancer cells, undergo inefficient relaxivity, and can be cytotoxic. We propose
a new class of "smart" MRI agents that become activated selectively at cancer sites. For this proposal, the MRI agents will be turned "on" through selective enzymatic hydrolysis via cathepsin B, an enzyme that is overexpressed by many cancer cells. Not only will this method greatly enhance the intensity of the signal at cancerous over healthy cells and tissues, but the proposed agents should be less toxic and demonstrate greater relaxivity as compared to traditional Gd3+ based MRI agents. Furthermore, the proposed agents could enter cells in an energy independent process to give smart MRI agents that operate within cells. Future applications include equipping the MRI agents with targeting agents for greater cell/tissue selectivity. To detect cancers that do not overexpress suitable enzymes, different types of switches will be attached that will respond to redox chemistry or changes in pH. The specific aims of this proposal are to create MRI agents, which can be optimized in the "off" and "on" modes, test their response to cathepsin B, measure their relaxivity values, and to determine their toxicities in cells and mice. The long-term goal is to provide researchers and the medical community tailor made smart MRI agents to advance the study of cellular functions and provide early detection of diseases, such as cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Smart, enzyme-activated MRI contrast agents for cancer detection
-
批准号:8302566
-
项目类别:
-
资助金额:$15.7万
-
财政年份:2012
-
负责人:DAVID B SMITHRUD
-
依托单位:
海外基金